Ronald J. Berenson

Positive selection of viable cell populations using avidin-biotin immunoadsorption.

We have developed a new method for the selective enrichment of lymphoid subpopulations from dog and human bone marrow and peripheral blood. A mononuclear cell preparation was treated successively with monoclonal antibody, biotinylated goat anti-mouse immunoglobulin and passed over a column containing avidin linked to polyacrylamide or Sepharose beads. Adherent cells were recovered by mechanical agitation and analyzed by immunofluorescence staining and fluorescence-activated cell sorter analysis. Dog bone marrow mononuclear cells were treated successively with the antibody 7.2, which recognizes the Ia-antigen, 1:500 dilution of biotinylated goat anti-mouse immunoglobulin and passed over avidin-Biogel (1 mg/ml) at a flow rate of 3.0 ml/min. Enrichment from a starting population that was 24.4 +/- 9.1% 7.2-positive to 78.3 +/- 6.8% 7.2-positive adherent cell population was observed with 47.7 +/- 7.8% recovery of 7.2-positive cells. Human bone marrow mononuclear cells were treated successively with the T cell antibody Leu-4 followed by 1:500 dilution of B-GAMIg and passed over a column of avidin-Biogel (1 mg/ml) at a flow rate of 1.5 ml/min. Enrichment from 7.2 +/- 3.3% Leu-4-positive cells in the starting cell population to 73.1 +/- 6.8% Leu-4-positive cells in the adherent cell population with total recovery of Leu-4-positive cells averaging 64.0 +/- 12.7%. Human bone marrow mononuclear cells positively selected with antibody Leu-4 or another T cell antibody, Leu-5 had a markedly enhanced response to the T cell mitogen, phytohemagglutinin compared to untreated bone marrow. Enrichment of a subpopulation of lymphocytes from dog peripheral blood mononuclear cells has been accomplished using antibody DT2, which reacts with a broad spectrum of dog lymphocytes. Nonspecific cell binding is primarily limited to granulocytes and monocytes. Future work is being directed at improving recovery of positively selected cells, reducing nonspecific cell binding and applying the technique to the selective enrichment of hematopoietic stem cells from bone marrow.

Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs

Purpose: Epithelial junctions between tumor cells inhibit the penetration of anticancer drugs into tumors. We previously reported on recombinant adenovirus serotype 3–derived protein (JO-1), which triggers transient opening of intercellular junctions in epithelial tumors through binding to desmoglein 2 (DSG2), and enhances the antitumor effects of several therapeutic monoclonal antibodies. The goal of this study was to evaluate whether JO-1 cotherapy can also improve the efficacy of chemotherapeutic drugs. Experimental Design: The effect of intravenous application of JO-1 in combination with several chemotherapy drugs, including paclitaxel/Taxol, nanoparticle albumin–bound paclitaxel/Abraxane, liposomal doxorubicin/Doxil, and irinotecan/Camptosar, was tested in xenograft models for breast, colon, ovarian, gastric and lung cancer. Because JO-1 does not bind to mouse cells, for safety studies with JO-1, we also used human DSG2 (hDSG2) transgenic mice with tumors that overexpressed hDSG2. Results: JO-1 increased the efficacy of chemotherapeutic drugs, and in several models overcame drug resistance. JO-1 treatment also allowed for the reduction of drug doses required to achieve antitumor effects. Importantly, JO-1 coadmininstration protected normal tissues, including bone marrow and intestinal epithelium, against toxic effects that are normally associated with chemotherapeutic agents. Using the hDSG2-transgenic mouse model, we showed that JO-1 predominantly accumulates in tumors. Except for a mild, transient diarrhea, intravenous injection of JO-1 (2 mg/kg) had no critical side effects on other tissues or hematologic parameters in hDSG2-transgenic mice. Conclusions: Our preliminary data suggest that JO-1 cotherapy has the potential to improve the therapeutic outcome of cancer chemotherapy. Clin Cancer Res; 18(12); 3340–51. ©2012 AACR.

Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.

We have developed a technology that depletes the complement regulatory protein (CRP) CD46 from the cell surface, and thereby sensitizes tumor cells to complement-dependent cytotoxicity triggered by therapeutic monoclonal antibodies (mAbs). This technology is based on a small recombinant protein, Ad35K++, which induces the internalization and subsequent degradation of CD46. In preliminary studies, we had demonstrated the utility of the combination of Ad35K++ and several commercially available mAbs such as rituximab, alemtuzumab, and trastuzumab in enhancing cell killing in vitro as well as in vivo in murine xenograft and syngeneic tumor models. We have completed scaled manufacturing of Ad35K++ protein in Escherichia coli for studies in nonhuman primates (NHPs). In macaques, we first defined a dose of the CD20-targeting mAb rituximab that did not deplete CD20-positive peripheral blood cells. Using this dose of rituximab, we then demonstrated that pretreatment with Ad35K++ reconstituted near complete elimination of B cells. Further studies demonstrated that the treatment was well tolerated and safe. These findings in a relevant large animal model provide the rationale for moving this therapy forward into clinical trials in patients with CD20-positive B-cell malignancies.

Long-Term Comparison of Immunosuppressive Therapy with Antithymocyte Globulin to Bone Marrow Transplantation in Aplastic Anemia

Treatment recommendations for aplastic anemia are based on long-term survival data for recipients of syngeneic or allogeneic bone marrow transplants (BMT) and the more recent results of “immunosuppressive therapy” (1ST), which usually includes antihuman thymocyte globulin (ATG) or antihuman lymphoblast globulin (ALG). Patient age and availability of a suitable marrow donor limit the number of patients who are potential candidates for marrow grafting. Many centers will not recommend an allogeneic BMT for patients with aplasia who are over 40 years of age, although some extend the upper age limit to 50 years. Suitable marrow donors include identical twins, genotypically HLA-identical siblings, or phenotypically HLA-identical family members. Transplants using HLA-mismatched family members or phenotypically identical, unrelated donors are usually reserved for “salvage” therapy after failure of a nontransplant treatment regimen.